Delivery of an Ectonucleotidase Inhibitor with ROS-Responsive Nanoparticles Overcomes Adenosine-Mediated Cancer Immunosuppression

The authors demonstrated that tumor microenvironment reprograming set the stage for response to anti-programmed cell death protein 1 (PD1) immunotherapy, and the combination resulted in tumor regression in a 4T1 breast cancer mouse model that was resistant to PD1 blockade.